CN115315447A - 免疫激活多特异性抗原结合分子及其用途 - Google Patents

免疫激活多特异性抗原结合分子及其用途 Download PDF

Info

Publication number
CN115315447A
CN115315447A CN202180020903.4A CN202180020903A CN115315447A CN 115315447 A CN115315447 A CN 115315447A CN 202180020903 A CN202180020903 A CN 202180020903A CN 115315447 A CN115315447 A CN 115315447A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202180020903.4A
Other languages
English (en)
Chinese (zh)
Inventor
直井壮太朗
冯舒
颜素婉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN115315447A publication Critical patent/CN115315447A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180020903.4A 2020-03-31 2021-03-30 免疫激活多特异性抗原结合分子及其用途 Withdrawn CN115315447A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020062357 2020-03-31
JP2020-062357 2020-03-31
PCT/JP2021/013456 WO2021200896A1 (en) 2020-03-31 2021-03-30 Immune activating multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
CN115315447A true CN115315447A (zh) 2022-11-08

Family

ID=77928944

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020903.4A Withdrawn CN115315447A (zh) 2020-03-31 2021-03-30 免疫激活多特异性抗原结合分子及其用途

Country Status (9)

Country Link
US (1) US20230147840A1 (enExample)
EP (1) EP4126958A4 (enExample)
JP (1) JP2021175391A (enExample)
KR (1) KR20220161156A (enExample)
CN (1) CN115315447A (enExample)
AR (1) AR121692A1 (enExample)
SG (1) SG11202105566TA (enExample)
TW (1) TW202204410A (enExample)
WO (1) WO2021200896A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2647707T (lt) * 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
MX389442B (es) 2013-11-11 2025-03-20 Chugai Pharmaceutical Co Ltd Región variable de anticuerpo modificada que contiene molécula de unión al antígeno.
WO2016076345A1 (ja) 2014-11-11 2016-05-19 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
WO2019232523A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
EP4413043A4 (en) * 2021-10-07 2025-11-12 Nat Res Council Canada Single-domain anti-BCMA antibodies and therapeutic constructs
CA3234068A1 (en) * 2021-10-07 2023-04-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
WO2025109518A1 (en) * 2023-11-21 2025-05-30 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms
WO2025210181A1 (en) * 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025226541A2 (en) * 2024-04-26 2025-10-30 Janssen Biotech, Inc. Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TW201938194A (zh) * 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
SG11202102882YA (en) * 2018-09-28 2021-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule comprising altered antibody variable region
SG11202101912UA (en) * 2018-09-28 2021-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用

Also Published As

Publication number Publication date
SG11202105566TA (en) 2021-11-29
AR121692A1 (es) 2022-06-29
EP4126958A1 (en) 2023-02-08
WO2021200896A1 (en) 2021-10-07
JP2021175391A (ja) 2021-11-04
KR20220161156A (ko) 2022-12-06
US20230147840A1 (en) 2023-05-11
TW202204410A (zh) 2022-02-01
EP4126958A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
CN115397866B (zh) 靶向dll3的多特异性抗原结合分子及其用途
CN115315447A (zh) 免疫激活多特异性抗原结合分子及其用途
KR102431028B1 (ko) 클로딘-6을 표적으로 하는 다중 특이성 항원 결합 분자 및 그의 사용
CN115335410A (zh) 生产多特异性抗原结合分子的方法
TWI900776B (zh) 密連蛋白6靶向多特異性抗原結合分子及其用途
HK40074344A (en) Immune activating multispecific antigen binding molecules and uses thereof
EA049685B1 (ru) Таргетирующие dll3 мультиспецифические антигенсвязывающие молекулы и их применения
HK40076462A (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
HK40076462B (zh) 靶向 dll3 的多特异性抗原结合分子及其用途
EA047044B1 (ru) Таргетирующие клаудин-6 мультиспецифические антигенсвязывающие молекулы и их применения
HK40076266A (en) Claudin-6 targeting multispecific antigen binding molecules and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074344

Country of ref document: HK

WW01 Invention patent application withdrawn after publication

Application publication date: 20221108

WW01 Invention patent application withdrawn after publication